Prazák J, Mĕricka O, Chytrý J
Institute of Haematology and Blood Transfusion, Prague, Czechoslovakia.
J Cancer Res Clin Oncol. 1990;116(5):525-7. doi: 10.1007/BF01613006.
HLA-A and B antigens were determined in a study of 162 patients (93 epidermoid type, 20 adenocarcinoma, 26 small-cell carcinoma and 23 undifferentiated types) with lung cancer. Differences between antigen frequencies in cancer and control populations were studied by chi 2Y analysis or Fisher's exact test. Survival data were analyzed using Cox's model for censored data. Cancer patients had a decreased frequency of the antigen HLA-B40 (chi 2Y = 14.15, P = 0.00018, Pc = 0.003, relative risk = 0.21). Patients with HLA-A10, A 11 and B27 had a shortened mean survival time. Patients with HLA-B12 had a prolonged survival time.
在一项针对162例肺癌患者（93例表皮样癌、20例腺癌、26例小细胞癌和23例未分化癌）的研究中，测定了HLA - A和B抗原。通过卡方检验或费舍尔精确检验研究癌症患者群体与对照群体中抗原频率的差异。使用Cox删失数据模型分析生存数据。癌症患者中抗原HLA - B40的频率降低（卡方检验=14.15，P = 0.00018，校正P = 0.003，相对风险=0.21）。携带HLA - A10、A11和B27的患者平均生存时间缩短。携带HLA - B12的患者生存时间延长。
